



July 10, 2025

To initiate joint research aiming to create innovative cancer drugs in Targeted Alpha Therapy

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director, President & CEO: Akihiro Tsujimura, "MTPC") has initiated joint research in Japan with Veneno Technologies Co., Ltd. (Headquarters: Tsukuba City, Ibaraki, President: Toshinori Yoshikawa, "Veneno") and Alpha Fusion Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, CEO: Sunao Fujioka, "Alpha Fusion") on the development of Targeted Alpha Therapy (TAT*) starting from the end of June 2025.

In this joint research, the three entities combine Veneno's unique peptide acquisition technology "PERISS™ method"*** with the novel alpha-emitter "Astatine-211" platform developed by Alpha Fusion to target cancer cells with high precision and create next-generation therapeutic drugs. Veneno's technology stands out for its ability to create Disulfide-Rich Peptide (DRP) with high stability *in vivo* and superior target selectivity compared to conventional linear peptides. On the other hand, Alpha Fusion's Astatine-211 and its technology provide a new TAT approach with enhanced safety and flexible dosing design, offering new treatment options for patients with cancers that are difficult to treat with existing therapies.

MTPC aims to create new innovations in cancer treatment by integrating the advanced technologies of both companies, providing more effective treatment options for patients and contributing to the improvement of the quality of life for many patients. This joint research is conducted based on separate contracts between MTPC, Veneno, and Alpha Fusion. By leveraging the strengths of each company, the three entities aim to integrate peptide technology, alpha-emitter platforms, and pharmaceutical development expertise to rapidly bring next-generation cancer treatment drugs.

MTPC will be committed to leveraging our accumulated R&D capabilities and promoting open innovation to create innovative pharmaceuticals that meet unmet medical needs.

* Targeted Alpha Therapy (TAT) is a new treatment method that accumulates alpha emitter in cancer cells. Due to the high energy and extremely short range of alpha emitter, this therapy can efficiently kill cancer cells while minimizing the impact on surrounding normal cells.

** The PERISS™ method is an advanced technology developed by Veneno Technologies that utilizes a systematically constructed DRP library to rapidly and efficiently discover high selectivity DRPs for membrane proteins.

<p style="text-align: center;">Contact: Mitsubishi Tanabe Pharma Corporation CEO Office PR Group +81-6-6205-5119</p>

【Reference】

■ About Veneno Technologies Co., Ltd.

Veneno Technologies Co., Ltd. is a biotech company established in 2020 based on technology seeds from the National Institute of Advanced Industrial Science and Technology (AIST). Veneno Technologies Co., Ltd. promotes open innovation in the fields of pharmaceuticals, agrochemicals, and animal health, with a focus on their unique product development platform "Veneno Suite" utilizing Disulfide-Rich Peptide (DRP). Veneno Technologies Co., Ltd. is advancing new drug development targeting membrane proteins and the development of environmentally friendly agrochemicals and feed additives, engaging in joint research with pharmaceutical companies and chemical manufacturers. With revenue structures such as technology access fees and licensing agreements, Veneno Technologies Co., Ltd. aims to create products that contribute to global health and environmental conservation.

■ About Alpha Fusion Co., Ltd.

Alpha Fusion Co., Ltd. was founded based on research results from Osaka University and the Japan Science and Technology Agency (JST) with the aim of practicalizing Astatine drug discovery. In the rapidly expanding field of Targeted Alpha Therapy (TAT), Alpha Fusion Co., Ltd. mission is to maximize the potential of Astatine therapy, transforming the lives of all patients and their families affected by cancer into ones filled with hope and understanding.